Abstract

BackgroundOxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers.MethodsConsecutive patients with PsA (who met the CASPAR classification criteria for PsA) and PsO were recruited from the Rheumatology Outpatient Clinic. A thorough clinical examination was performed, including entheseal (Leeds enthesitis index (LEI)) and joint involvement (SJC/TJC 66/68). Patients were evaluated for pain and global disease activity on a visual analog scale (VAS) ranging from 0 to 100. This was followed by disease activity scores calculation: cDAPSA (Disease Activity Index for Psoriatic Arthritis) and Psoriasis Area and Severity Index (PASI). Serum oxylipins were determined by mass spectrometry and their association with clinical characteristics (PASI/LEI and cDAPSA) was analyzed using Metaboanalyst 4.0 and R version 3.6.1.ResultsTwenty PsO (average age 52 [10.8], 55% males) and 19 PsA patients (average age 60.5 [11.4], 63.1% males) were included. PsO patients had an average body mass index (BMI) of 33.7 (6.84) and an average PASI of 3.8 (4.2). PsA patients had an average BMI of 31.9 (5.6), TJC of 9.3 (10.41), SJC of 3.7 (4.23), with an average cDAPSA of 23.3 (11.4). 63.1% of PsA patients had enthesitis (average LEI 2.2 [3]) and the same percentage had psoriasis (average PASI 3(5]). Sera were analyzed for oxylipin levels. PsO and PsA patients with higher PASI score (> 2.5) had significantly lower serum concentrations of pro-inflammatory oxylipins, most of them arachidonic acid derived (AA). Oxylipin profiling did not associate with cDAPSA. Interestingly, several AA-derived oxylipins (5,15 di-HETE (5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid), 5-oxoETE (5-Oxo-eicosatetraenoic acid), PGE2 (prostaglandin E2), 11bPGE2 (11 beta prostaglandin D2), and LTB4 (leukotriene B4)) were significantly increased in PsA patients with enthesitis compared to those without.ConclusionsThe AA-derived proinflammatory oxylipins were lower in both PsO and PsA patients with higher skin scores. Joint disease activity was not associated with the concentrations of oxylipins. Yet, enthesitis was associated with an increase of AA-derived pro-inflammatory oxylipins in PsA patients. Further studies are needed to determine whether oxylipin profiling can be a good biomarker of enthesitis in PsA patients.

Highlights

  • Psoriatic arthritis (PsA) is a systemic inflammatory disease that involves, in addition to axial and peripheral arthritis, extraarticular manifestations, including nail changes, dactylitis, and enthesitis [1]

  • Enthesitis was associated with an increase of arachidonic acid (AA)-derived pro-inflammatory oxylipins in psoriatic arthritis (PsA) patients

  • In a previous publication from our group [5], we described several AA-derived proinflammatory oxylipins and eicosapentaenoic acid (EPA)-derived anti-inflammatory oxylipins which correlated with joint disease, suggesting that an imbalance between pro- and anti-inflammatory oxylipins could be involved in the pathogenesis of PsA

Read more

Summary

Introduction

Psoriatic arthritis (PsA) is a systemic inflammatory disease that involves, in addition to axial and peripheral arthritis, extraarticular manifestations, including nail changes, dactylitis, and enthesitis [1]. The etiology and pathogenesis of PsA is not fully understood but involves a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation of the skin and joints [2]. The risk factors that predispose patients to develop PsA, psoriasis (PsO), and other extraarticular manifestations do not always overlap, and joint, skin, and enthesis do not respond to the same extent to some of the current therapies, suggesting an underlying heterogeneity of its physiopathology [3]. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. We compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call